Implementation Process Article 5(3) Nitrosamine
Official address Domenico Scarlattilaan 6 1083 HS Amsterdam The Netherlands An agency of the European Union Address for visits and deliveries Refer to Send us a question Go to Telephone +31 (0)88 781 6000 European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/425645/2020 22 February 2021 European Medicines Regulatory Network approach for the Implementation of the CHMP Opinion pursuant to Article 5(3) of Regulation (EC) No 726/2004 for Nitrosamine impurities in human medicines European Medicines Regulatory Network approach for the Implementation of the CHMP Opinion pursuant to Article 5(3) of Regulation (EC) No 726/2004 for Nitrosamine impurities in human medicines EMA/425645/2020 Page 2/14 Table of contents 1. Background ........................................ ........................................ .............. 3 2. Conclusions of the CHMP review.
contact points as outlined on the EMA and CMDh websites. If the N-nitrosamine(s) identified exceed(s) the AI limit based on the ICH M7 principles, an investigation report should be submitted as part of the step 2 response (see chapter 3.1. for further
Download Implementation Process Article 5(3) Nitrosamine
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: